This document contains forward-looking statements. These statements are not historical facts. These statements include forecasts and estimates as well as hypotheses on which they are based, statements regarding projects, objectives, intentions and expectations regarding financial results, events, operations, future services, the development of products and their potential or future performance. Such forward-looking statements can often be identified by the words “expect to”, “anticipate”, “believe”, “intend to”, “estimate” or “plan” and similar expressions. Although Sanofi management believes that these forward-looking statements are reasonable, investors are alerted to the fact that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond the control of Sanofi, which may imply that results and actual events differ significantly from those that are expressed, induced or foreseen in forward-looking statements and information. These risks and uncertainties include uncertainties inherent in research and development, future clinical data and analyses, including those subsequent to market launch, decisions by regulatory authorities, such as the FDA and EMA, approval or not, and on what date, of the filing of a drug application, a process or a biological product for one of these candidate products as well as their decisions regarding labeling and other factors that may affect the availability or the commercial potential of these candidate products, the absence of guarantee that candidate products, if approved, will be a commercial success, the future approval and commercial success of therapeutic alternatives, the ability of the Group to seize external growth opportunities, changes in foreign exchange and interest rates, the impact of the operational cost control policy and evolution of costs, the average number of shares outstanding as well as those that are developed or identified in public documents filed by Sanofi to the authority financial markets (AMF) and the Securities and Exchange Commission (SEC), including those listed under the headings “Risk factors” and “Forward-looking statements” in the 2015 Sanofi reference document which was filed with the AMF, as well as under the headings “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” on Sanofi’s Form 20F, filed with the SEC. Sanofi makes no commitment to update the information and forward-looking statements subject to applicable regulations, namely articles 223-1 et seq. of the general regulations of the AMF.